EditorialEditorial

Next-generation sequencing and its clinical application

Dahui Qin
Cancer Biology & Medicine February 2019, 16 (1) 4-10; DOI: https://doi.org/10.20892/j.issn.2095-3941.2018.0055

References

  1. 1.↵
    2. Schuster SC.
    Next-generation sequencing transforms today's biology. Nat Methods. 2008; 5: 16–8.
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.
    2. Margulies M,
    3. Egholm M,
    4. Altman WE,
    5. Attiya S,
    6. Bader JS,
    7. Bemben LA, et al.
    Genome sequencing in microfabricated high-density picolitre reactors. Nature. 2005; 437: 376–80.
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.
    2. Shendure J,
    3. Porreca GJ,
    4. Reppas NB,
    5. Lin XX,
    6. McCutcheon JP,
    7. Rosenbaum AM, et al.
    Accurate multiplex polony sequencing of an evolved bacterial genome. Science. 2005; 309: 1728–32.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    2. Shendure J,
    3. Mitra RD,
    4. Varma C,
    5. Church GM.
    Advanced sequencing technologies: methods and goals. Nat Rev Genet. 2004; 5: 335–44.
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    2. Sanger F,
    3. Nicklen S,
    4. Coulson AR.
    DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA. 1977; 74: 5463–7.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    2. Knierim E,
    3. Lucke B,
    4. Schwarz JM,
    5. Schuelke M,
    6. Seelow D.
    Systematic comparison of three methods for fragmentation of long-range PCR products for next generation sequencing. PLoS One. 2011; 6: e28240.
  7. 7.↵
    2. Albert TJ,
    3. Molla MN,
    4. Muzny DM,
    5. Nazareth L,
    6. Wheeler D,
    7. Song XZ, et al.
    Direct selection of human genomic loci by microarray hybridization. Nat Methods. 2007; 4: 903–5.
    OpenUrlCrossRefPubMedWeb of Science
  8. 8.↵
    2. Bau S,
    3. Schracke N,
    4. Kränzle M,
    5. Wu HG,
    6. Stähler PF,
    7. Hoheisel JD, et al.
    Targeted next-generation sequencing by specific capture of multiple genomic loci using low-volume microfluidic DNA arrays. Anal Bioanal Chem. 2009; 393: 171–5.
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.↵
    2. Chang FQ,
    3. Li MM.
    Clinical application of amplicon-based next-generation sequencing in cancer. Cancer Genet. 2013; 206: 413–9.
    OpenUrlCrossRefPubMedWeb of Science
  10. 10.↵
    2. Kohlmann A,
    3. Grossmann V,
    4. Haferlach T.
    Integration of next-generation sequencing into clinical practice: are we there yet? Semin Oncol. 2012; 39: 26–36.
    OpenUrlCrossRefPubMed
  11. 11.↵
    2. Gargis AS,
    3. Kalman L,
    4. Bick DP,
    5. da Silva C,
    6. Dimmock DP,
    7. Funke BH, et al.
    Good laboratory practice for clinical next-generation sequencing informatics pipelines. Nat Biotechnol. 2015; 33: 689–93.
    OpenUrlCrossRefPubMed
  12. 12.↵
    2. Swerdlow SH,
    3. Campo E,
    4. Harris NL,
    5. Jaffe ES,
    6. Pileri SA,
    7. Stein H, et al.
    WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2017; 586.
  13. 13.↵
    2. Greenberg PL,
    3. Stone RM,
    4. Al-Kali A,
    5. Barta SK,
    6. Bejar R,
    7. Bennett JM, et al.
    Myelodysplastic syndromes, version 2.2017, NCCN clinical practice guidelines in oncologys. J Natl Compr Canc Netw. 2017; 15: 60–87.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    2. Ferrando AA,
    3. López-Otín C.
    Clonal evolution in leukemia. Nat Med. 2017; 23: 1135–45.
    OpenUrlCrossRefPubMed
  15. 15.
    2. Venuat AM,
    3. Dutrillaux B,
    4. Rosenfeld C.
    A late clonal evolution of a human leukemic line: sequential cytogenetic studies. Eur J Cancer. 1977; 13: 123–30.
    OpenUrl
  16. 16.
    2. Verhest A,
    3. Lustman F,
    4. Wittek M,
    5. van Schoubroeck F,
    6. Naets JP.
    Cytogenetic evidence of clonal evolution in 5q- anemia. Biomedicine. 1977; 27: 211–2.
    OpenUrlPubMed
  17. 17.↵
    2. Shah SP,
    3. Roth A,
    4. Goya R,
    5. Oloumi A,
    6. Ha G,
    7. Zhao YJ, et al.
    The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature. 2012; 486: 395–9.
    OpenUrlCrossRefPubMedWeb of Science
  18. 18.↵
    2. Ding L,
    3. Ley TJ,
    4. Larson DE,
    5. Miller CA,
    6. Koboldt DC,
    7. Welch JS, et al.
    Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature. 2012; 481: 506–10.
    OpenUrlCrossRefPubMedWeb of Science
  19. 19.↵
    2. Mikhaylenko DS,
    3. Efremov GD,
    4. Strelnikov VV,
    5. Zaletaev DV,
    6. Alekseev BY.
    Somatic mutation analyses in studies of the clonal evolution and diagnostic targets of prostate cancer. Curr Genomics. 2017; 18: 236–43.
    OpenUrl
  20. 20.↵
    2. Gerlinger M,
    3. Rowan AJ,
    4. Horswell S,
    5. Larkin J,
    6. Endesfelder D,
    7. Gronroos E, et al.
    Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012; 366: 883–92.
    OpenUrlCrossRefPubMedWeb of Science
  21. 21.↵
    2. Sherwood J,
    3. Dearden S,
    4. Ratcliffe M,
    5. Walker J.
    Mutation status concordance between primary lesions and metastatic sites of advanced non-small-cell lung cancer and the impact of mutation testing methodologies: a literature review. J Exp Clin Cancer Res. 2015; 34: 92.
    OpenUrl
  22. 22.↵
    2. Yachida S,
    3. Jones S,
    4. Bozic I,
    5. Antal T,
    6. Leary R,
    7. Fu BJ, et al.
    Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature. 2010; 467: 1114–7.
    OpenUrlCrossRefPubMedWeb of Science
  23. 23.↵
    2. Steuer CE,
    3. Ramalingam SS.
    Tumor mutation burden: leading immunotherapy to the era of precision medicine? J Clin Oncol. 2018; 36: 631–2.
    OpenUrlCrossRef
  24. 24.↵
    2. Yohe S,
    3. Hauge A,
    4. Bunjer K,
    5. Kemmer T,
    6. Bower M,
    7. Schomaker M, et al.
    Clinical validation of targeted next-generation sequencing for inherited disorders. Arch Pathol Lab Med. 2015; 139: 204–10.
    OpenUrlCrossRefPubMed
  25. 25.↵
    2. Jennings LJ,
    3. Arcila ME,
    4. Corless C,
    5. Kamel-Reid S,
    6. Lubin IM,
    7. Pfeifer J, et al.
    Guidelines for validation of next-generation sequencing-based oncology panels: a joint consensus recommendation of the association for molecular pathology and college of american pathologists. J Mol Diagn. 2017; 19: 341–65.
    OpenUrlCrossRefPubMed
  26. 26.↵
    2. Matthijs G,
    3. Souche E,
    4. Alders M,
    5. Corveleyn A,
    6. Eck S,
    7. Feenstra I, et al.
    Guidelines for diagnostic next-generation sequencing. Eur J Hum Genet. 2016; 24: 2–5.
    OpenUrlCrossRefPubMed
  27. 27.↵
    2. Ettinger DS,
    3. Wood DE,
    4. Aisner DL,
    5. Akerley W,
    6. Bauman J,
    7. Chirieac LR, et al.
    Non-small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2017; 15: 504–35.
    OpenUrlAbstract/FREE Full Text
  28. 28.↵
    2. Salgia R.
    Mutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma. Expert Rev Mol Diagn. 2016; 16: 737–49.
    OpenUrl
  29. 29.
    2. Sholl LM,
    3. Aisner DL,
    4. Varella-Garcia M,
    5. Berry LD,
    6. Dias-Santagata D,
    7. Wistuba II, et al.
    Multi-institutional oncogenic driver mutation analysis in lung adenocarcinoma: the lung cancer mutation consortium experience. J Thorac Oncol. 2015; 10: 768–77.
    OpenUrlCrossRefPubMed
  30. 30.
    2. Pao W,
    3. Girard N.
    New driver mutations in non-small-cell lung cancer. Lancet Oncol. 2011; 12: 175–80.
    OpenUrlCrossRefPubMedWeb of Science
  31. 31.↵
    2. Faehling M,
    3. Schwenk B,
    4. Kramberg S,
    5. Eckert R,
    6. Volckmar AL,
    7. Stenzinger A, et al.
    Oncogenic driver mutations, treatment, and EGFR-TKI resistance in a caucasian population with non-small cell lung cancer: survival in clinical practice. Oncotarget. 2017; 8: 77897–914.
    OpenUrl
  32. 32.↵
    2. Takeda M,
    3. Sakai K,
    4. Terashima M,
    5. Kaneda H,
    6. Hayashi H,
    7. Tanaka K, et al.
    Clinical application of amplicon-based next-generation sequencing to therapeutic decision making in lung cancer. Ann Oncol. 2015; 26: 2477–82.
    OpenUrlCrossRefPubMed
  33. 33.↵
    2. Wing MR,
    3. Reeser JW,
    4. Smith AM,
    5. Reeder M,
    6. Martin D,
    7. Jewell BM, et al.
    Analytic validation and real-time clinical application of an amplicon-based targeted gene panel for advanced cancer. Oncotarget. 2017; 8: 75822–33.
    OpenUrl
  34. 34.↵
    2. Hagemann IS,
    3. Cottrell CE,
    4. Lockwood CM.
    Design of targeted, capture-based, next generation sequencing tests for precision cancer therapy. Cancer Genet. 2013; 206: 420–31.
    OpenUrlCrossRefPubMed
  35. 35.↵
    2. Yan B,
    3. Hu YL,
    4. Ng C,
    5. Ban KHK,
    6. Tan TW,
    7. Huan PT, et al.
    Coverage analysis in a targeted amplicon-based next-generation sequencing panel for myeloid neoplasms. J Clin Pathol. 2016; 69: 801–4.
    OpenUrlAbstract/FREE Full Text
  36. 36.↵
    2. Luthra R,
    3. Chen H,
    4. Roy-Chowdhuri S,
    5. Singh RR.
    Next-generation sequencing in clinical molecular diagnostics of cancer: advantages and challenges. Cancers (Basel). 2015; 7: 2023–36.
    OpenUrl
  37. 37.
    2. Deans ZC,
    3. Costa JL,
    4. Cree I,
    5. Dequeker E,
    6. Edsjö A,
    7. Henderson S, et al.
    Integration of next-generation sequencing in clinical diagnostic molecular pathology laboratories for analysis of solid tumours; an expert opinion on behalf of IQN Path ASBL. Virchows Arch. 2017; 470: 5–20.
    OpenUrl
  38. 38.↵
    2. Gargis AS,
    3. Kalman L,
    4. Berry MW,
    5. Bick DP,
    6. Dimmock DP,
    7. Hambuch T, et al.
    Assuring the quality of next-generation sequencing in clinical laboratory practice. Nat Biotechnol. 2012; 30: 1033–6.
    OpenUrlCrossRefPubMed
  39. 39.↵
    2. Santos R,
    3. Ursu O,
    4. Gaulton A,
    5. Bento AP,
    6. Donadi RS,
    7. Bologa CG, et al.
    A comprehensive map of molecular drug targets. Nat Rev Drug Discov. 2017; 16: 19–34.
    OpenUrlCrossRefPubMed
  40. 40.↵
    2. Melis C,
    3. Rogiers A,
    4. Bechter O,
    5. van den Oord JJ.
    Molecular genetic and immunotherapeutic targets in metastatic melanoma. Virchows Arch. 2017; 471: 281–93.
    OpenUrl
  41. 41.↵
    2. Sun JC,
    3. Wei Q,
    4. Zhou YB,
    5. Wang JQ,
    6. Liu Q,
    7. Xu H.
    A systematic analysis of FDA-approved anticancer drugs. BMC Syst Biol. 2017; 11: 87.
    OpenUrl
  42. 42.↵
    2. Bunnell AE,
    3. Garby CA,
    4. Pearson EJ,
    5. Walker SA,
    6. Panos LE,
    7. Blum JL.
    The clinical utility of next generation sequencing results in a community-based hereditary cancer risk program. J Genet Couns. 2017; 26: 105–12.
    OpenUrl
  43. 43.↵
    2. Gomy I,
    3. Del Pilar Estevez Diz M.
    Hereditary cancer risk assessment: insights and perspectives for the Next-Generation Sequencing era. Genet Mol Biol. 2016; 39: 184–8.
    OpenUrl
  44. 44.↵
    2. Gorgannezhad L,
    3. Umer M,
    4. Islam MN,
    5. Nguyen NT,
    6. Shiddiky MJA.
    Circulating tumor DNA and liquid biopsy: opportunities, challenges, and recent advances in detection technologies. Lab Chip. 2018; 18: 1174–96.
    OpenUrlCrossRef
  45. 45.
    2. Alix-Panabieres C,
    3. Pantel K.
    Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy. Cancer Discov. 2016; 6: 479–91.
    OpenUrlAbstract/FREE Full Text
  46. 46.
    2. Cheng FF,
    3. Su L,
    4. Qian C.
    Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer. Oncotarget. 2016; 7: 48832–41.
    OpenUrl
  47. 47.
    2. Heitzer E,
    3. Ulz P,
    4. Geigl JB.
    Circulating tumor DNA as a liquid biopsy for cancer. Clin Chem. 2015; 61: 112–23.
    OpenUrlAbstract/FREE Full Text
  48. 48.
    2. Komatsubara KM,
    3. Sacher AG.
    Circulating tumor DNA as a liquid biopsy: current clinical applications and future directions. Oncology (Williston Park). 2017; 31: 618–27.
    OpenUrl
  49. 49.↵
    2. Zhang W,
    3. Xia WJ,
    4. Lv ZY,
    5. Xin Y,
    6. Ni C,
    7. Yang L.
    Liquid biopsy for cancer: circulating tumor cells, circulating free DNA or exosomes? Cell Physiol Biochem. 2017; 41: 755–68.
    OpenUrl
  50. 50.↵
    2. Cohen JD,
    3. Javed AA,
    4. Thoburn C,
    5. Wong F,
    6. Tie J,
    7. Gibbs P, et al.
    Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers. Proc Natl Acad Sci USA. 2017; 114: 10202–7.
    OpenUrlAbstract/FREE Full Text
  51. 51.
    2. Offin M,
    3. Chabon JJ,
    4. Razavi P,
    5. Isbell JM,
    6. Rudin CM,
    7. Diehn M, et al.
    Capturing genomic evolution of lung cancers through liquid biopsy for circulating tumor DNA. J Oncol. 2017; 2017: 4517834.
    OpenUrlPubMed
  52. 52.
    2. Ono A,
    3. Fujimoto A,
    4. Yamamoto Y,
    5. Akamatsu S,
    6. Hiraga N,
    7. Imamura M, et al.
    Circulating tumor DNA analysis for liver cancers and its usefulness as a liquid biopsy. Cell Mol Gastroenterol Hepatol. 2015; 1: 516–34.
    OpenUrl
  53. 53.
    2. Payne K,
    3. Spruce R,
    4. Beggs A,
    5. Sharma N,
    6. Kong A,
    7. Martin T, et al.
    Circulating tumor DNA as a biomarker and liquid biopsy in head and neck squamous cell carcinoma. Head Neck. 2018; 40: 1598–1604.
    OpenUrl
  54. 54.
    2. Rossi G,
    3. Mu ZM,
    4. Rademaker AW,
    5. Austin LK,
    6. Strickland KS,
    7. Costa RLB, et al.
    Cell-free DNA and circulating tumor cells: comprehensive liquid biopsy analysis in advanced breast cancer. Clin Cancer Res. 2018; 24: 560–8.
    OpenUrlAbstract/FREE Full Text
  55. 55.
    2. Takai E,
    3. Yachida S.
    Circulating tumor DNA as a liquid biopsy target for detection of pancreatic cancer. World J Gastroenterol. 2016; 22: 8480–8.
    OpenUrl
  56. 56.
    2. Todenhöfer T,
    3. Struss WJ,
    4. Seiler R,
    5. Wyatt AW,
    6. Black PC.
    Liquid biopsy-analysis of circulating tumor DNA (ctDNA) in bladder cancer. Bladder Cancer. 2018; 4: 19–29.
    OpenUrl
  57. 57.↵
    2. Giannopoulou L,
    3. Kasimir-Bauer S,
    4. Lianidou ES.
    Liquid biopsy in ovarian cancer: recent advances on circulating tumor cells and circulating tumor DNA. Clin Chem Lab Med. 2018; 56: 186–97.
    OpenUrl
  58. 58.↵
    2. Papasavva T,
    3. van Ijcken WFJ,
    4. Kockx CEM,
    5. van den Hout MCGN,
    6. Kountouris P,
    7. Kythreotis L, et al.
    Next generation sequencing of SNPs for non-invasive prenatal diagnosis: challenges and feasibility as illustrated by an application to β-thalassaemia. Eur J Hum Genet. 2013; 21: 1403–10.
    OpenUrl
  59. 59.
    2. Stokowski R,
    3. Wang E,
    4. White K,
    5. Batey A,
    6. Jacobsson B,
    7. Brar H, et al.
    Clinical performance of non-invasive prenatal testing (NIPT) using targeted cell-free DNA analysis in maternal plasma with microarrays or next generation sequencing (NGS) is consistent across multiple controlled clinical studies. Prenat Diagn. 2015; 35: 1243–6.
    OpenUrlCrossRef
  60. 60.↵
    2. Xu XP,
    3. Gan HY,
    4. Li FX,
    5. Tian Q,
    6. Zhang J,
    7. Liang RL, et al.
    A method to quantify cell-free fetal DNA fraction in maternal plasma using next generation sequencing: its application in non-invasive prenatal chromosomal aneuploidy detection. PLoS One. 2016; 11: e0146997.
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section